Curriculum Vitae - College of Pharmacy - Nova Southeastern ...

A. LYMPEROPOULOS-CV 

Curriculum Vitae 

Education/Training: 

1) Post Doctoral Research Fellow in Molecular Cardiovascular Biology/Medicine, Thomas 

Jefferson University, Philadelphia, PA (09/2004 –07/2009) 

2) Ph.D. in Pharmacology, University of Patras, Patras, Greece (03/2000 - 02/2004) 

3) M.Sc. in “Medicinal Chemistry: Drug Design & Development”, University of Patras, Patras, 

Greece (10/1998 - 03/2000) 

4) B.Sc. in Pharmacy, University of Patras, Patras, Greece (10/1993 - 07/1998) 

Positions/Employment, Memberships and Honors: 

August 2009-Present: Assistant Professor of Pharmacology, Dept. of Pharmaceutical Sciences, 

College of Pharmacy, Nova Southeastern University, Davie/Ft. Lauderdale, FL. 

Duties: Teaching, Research, Administration. 

Research focus: Biology and regulation of G-protein coupled receptors (GPCRs), such as 

adrenergic receptors and receptors for angiotensin II, in the pathophysiology of heart failure 

and, more broadly, in the neurohormonal control of the circulation. The main goal is discovery 

of new and innovative drugs for countering the cardio-toxic actions of catecholamines and of 

angiotensin II (and also of other hormones) in heart failure. Particular focus is given on the role 

of these receptors in adrenal gland function in relation with the cardiovascular system, thus 

providing clues for new treatments for cardiovascular disease. The research utilizes cutting-edge 

in vivo gene therapy techniques to manipulate, for therapeutic purposes, various GPCR kinases 

(GRKs) and beta-arrestins, proteins that normally desensitize receptors (among other functions) 

and are involved in heart failure pathophysiology. 

August 2004-July 2009: PostDoctoral Research Fellow, Center for Translational 

Medicine, Thomas Jefferson University, Philadelphia, PA. 

Mentor: Dr. Walter J. Koch 

Research focus: Cardiovascular biology/pharmacology and gene therapy, with a particular 

interest in mechanisms of adrenergic system regulation in heart failure and in ways of 

manipulating these mechanisms for therapeutic purposes. In particular, novel roles of G-protein 

1


coupled receptor kinases and their co-factors, beta-arrestins, in regulation of various important 

cardiovascular G-protein coupled receptors are investigated. 

November 1998-November 2003: Graduate Research Assistant, Department of 

Pharmacology, School of Medicine, University of Patras, Patras, Greece 

Mentor: Dr. Chris S. Flordellis 

Doctorate thesis project: Study of signal transduction from wild-type and polymorphic 

human α 2 -adrenergic receptors. 

July 1997-August 1997: Visiting Undergraduate Lab Assistant, Department of Cell Biology, John 

Innes Centre, Norwich Research Park, England, UK 

Mentor: Dr. Liam Dolan 

Research objective: Additional training in molecular biology techniques. 

November 1997-September 1998: Undergraduate Lab Assistant, Department of Molecular 

Biology, University of Patras Medical School, Patras, Greece 

Mentors: Dr. Ioannis Zarkadis, Dr. Georgia Sotiropoulou 

Research project: Training in basic molecular biology techniques. 

Teaching Experience: 

2009-Present: Assistant Professor, Teaching undergraduate students of the PharmD 

Program and postgraduate students of the PhD program of the Nova Southeastern 

University`s College of Pharmacy. 

Specifically: 

Course Coordinator of the elective course “Individualized Pharmacotherapy” of the 

PharmD Program curriculum and of the core course “Applied Pharmacology” of the 

PhD Program curriculum. 

Instructor in core courses “Pharmacodynamics IV & V” of the PharmD Program 

curriculum and in core course “Molecular and Cellular Pharmacodynamics” of the 

PhD Program curriculum. 

Guest Lecturer in core course “Molecular Medicine & Pharmacogenomics” of the 

PhD Program curriculum and in elective course “Molecular Medicine” of the PharmD 

Program curriculum. 

2003: Guest Lecturer, Special Topics in Molecular Pharmacology and Biology, 

Graduate Courses Program in the “Basic Medical Sciences”, School of Medicine, 

University of Patras, Patras, Greece. 

2


1999: Adjunct instructor, Techniques in Molecular Pharmacology, Department of 

Pharmacology, School of Medicine, University of Patras, Patras, Greece. 

Professional Associations: 

American Heart Association, Premium Professional Member of the “Basic Cardiovascular 

Sciences (BCVS)” & the “Functional Genomics & Translational Biology” councils, since 2006. 

Heart Failure Society of America, Full Member at the early career/junior faculty level, since 

2007. 

American Association for the Advancement of Science (AAAS), member since February 2005. 

New York Academy of Sciences, member since October 2005. 

American Association of Colleges of Pharmacy (AACP), member since July 2008. 

American Chemical Society, member since April 2007. 

Greek Society of Pharmacology, member since March 2001. 

Greek Association of Pharmacists, member since February 2001. 

Greek Society of Biochemistry and Molecular Biology, member since June 1999. 

Honors and Awards: 

• November 12, 2011: Elected Fellow of the American Heart Association (FAHA) with its 

“Council on Basic Cardiovascular Sciences (BCVS)” 

• Recipient of AHA Scientist Development Grant (SDG) Award (National Center) entitled: 

“Role of adrenal beta-arrestin-1 in angiotensin II-induced aldosterone production in postinfarct 

heart failure” (Award ID: 09SDG2010138), Principal Investigator: A. Lymperopoulos, 

PhD, Duration: 07/01/2009-06/30/2014, Gross Annual Funding: $77,000 USD 

• 2006 Melvin L. Marcus Young Investigator Award in Cardiovascular Sciences Finalist, 

“Adrenal G-protein coupled Receptor Kinase 2 Up-regulation Mediates Sympathetic 

Overstimulation in Chronic Heart Failure”, American Heart Association Scientific Sessions 

2006, Chicago, IL,12-15 November 2006 

• 2010 Cardiovascular Research Award of the Council on Basic Cardiovascular Sciences of 

the European Society of Cardiology (ESC) Finalist, “Genetic deletion of β-arrestin-1 

improves function of the infarcted heart by reducing cardiac β-adrenergic receptor 

desensitization and cardiotoxic neurohormonal overstimulation”, Frontiers in 

3


Cardiovascular Biology Congress of the ESC Council on Basic Cardiovascular Sciences, Berlin, 

Germany, 16-19 July 2010 

• AHA Great Rivers (Formerly: Pennsylvania-Delaware) affiliate Post Doctoral Fellowship 

award Recipient (July 2005-June 2007) 

• AHA Great Rivers (Formerly: Pennsylvania-Delaware) affiliate Post Doctoral Fellowship 

award Recipient (One-year extension of above fellowship: July 2007-June 2008). 

Application received average priority score of 1.2778 (best possible: 1.0) and its percentile 

rank was 0.76 (best possible: 0.01) 

• 1st best oral presentation award winner at the 3rd Jefferson Postdoctoral Research 

symposium, held at Thomas Jefferson University, Philadelphia, PA, USA (24 June 2008) 

• 1st best poster presentation award winner at the 1st Jefferson Postdoctoral Research 

symposium, held at Thomas Jefferson University, Philadelphia, PA, USA (15 May 2006) 

• Research Abstract entitled: “Biased Agonism/Antagonism of β-arrestin Activation by the 

Angiotensin II Type 1 Receptor: a Study of Sartans and Angiotensin II Analogs Using 

Aldosterone Turnover as a Readout” selected for special honorary presentation at the 

“Best of AHA Specialty Conferences Poster Session: BCVS 2010”, November 15, 2010, 

2010 AHA Scientific Sessions, Chicago, IL, USA, as being a top-scoring abstract (among the 

top 10 percent of the accepted abstracts for that meeting) 

• Award for top of class graduating in the “M.Sc. in Medicinal Chemistry” post-graduate 

studies program Recipient, University of Patras, Patras, Greece (Class 2000) 

• Peer reviewer for the American Heart Association`s (AHA) Basic Cardiovascular Sciences 

(BCVS) council, both for scientific research grants submitted to AHA for funding and for 

scientific abstracts submitted to AHA Scientific Sessions 

• New Investigator Award (NIA) research grant peer reviewer for the American Association 

of Colleges of Pharmacy (AACP) 

• Research grant peer reviewer for the South African Medical Research Council (MRC) 

• Undergraduate student fellowship recipient for participation in the “Pharmacy Student 

Professional Training Program”, funded by the European Union Peripheral Development 

Support Framework, Scientific Research and Development Support Program II, 1997-1998 

• Graduate student fellowship recipient, European Union Peripheral Development Support 

Framework, Scientific Research and Development Support Program II, 1998-2000 

• Research fellowship recipient, BIOMED II Program, European Union Research Council, 

1998-2001 

4


• NATO/FEBS travel/participation grant award recipient, NATO/FEBS Advanced Study 

Institute-International Summer School on «Molecular Mechanisms of Signal Transduction», 

Island of Spetsai, Greece, 1999 

• HFSA Travel grant award recipient for participation at the 12th HFSA Annual Scientific 

Meeting, held in Toronto, Ontario, Canada, 21-24 September 2008 

• EMBO young scientist travel grant award recipient for participation in the EMBO Practical 

Course: “Advanced Techniques in Molecular Medicine”, organized by the Departments of 

Medical Sciences, and of Genetics and Pathology, Uppsala University, Uppsala, Sweden, 

2002 

Scholarly and Editorialist Honors and Activities: 

1) Associate Editor of “Pharmacology Research & Perspectives”, a peer-reviewed journal 

of the British Pharmacological Society, & Academic Editor of “Medicine”, a peerreviewed 

medical journal of the esteemed publisher Wolters Kluwer Health. 

2) Member of the Editorial Boards of the following peer-reviewed journals: “International 

Journal of Hematology Research” (since November 2014); “Heart Health” (since 

September 2014); “International Archives of Clinical Pharmacology” (since November 

2014); “Journal of Pharmacology and Pharmacovigilance” (since November 2014); 

“Toxicology and Allied Clinical Pharmacology” (since August 2014); “Chronic Diseases- 

International” (since August 2014); “Journal of Pharmacology & Pharmacogenomics” 

(since August 2014); “Journal of Addiction and Neuropharmacology” (since May 2014); 

“International Journal of Biochemistry Research & Review” (since April 2014); “Journal 

of Clinical Immunology and Immunotherapy” (since March 2014); “Journal of 

Endocrine System and Enzymology” (since August 2014); “Case Reports in Internal 

Medicine” (since December 2013); “World Journal of Cardiology” (since November 

2013); “World Journal of Biological Chemistry” (since November 2013); “Journal of 

Geriatric Cardiology” (since December 2013); “Journal of Cardiology and Therapy” 

(since October 2013); “Austin Journal of Pharmacology and Therapeutics” (since 

October 2013); “Journal of Clinical and Laboratory Investigation Updates” (since June 

2013); “Journal of Pharmacogenomics and Pharmacoproteomics” (since January 2013); 

“American Journal of Life Sciences” (since December 2012); “American Journal of 

Cardiovascular Disease” (since March 2011); “Journal of Carcinogenesis and 

Mutagenesis” (since July 2010); and “International Journal of Cancer Studies & 

Research (IJCR)” (since May 2012). 

3) Scientific manuscript reviewer for the following peer-reviewed journals: “Journal of 

Biological Chemistry”, “British Journal of Pharmacology”, “Circulation Research”, 

“Pharmacogenomics”, “American Journal of Cardiology”, “Hypertension”, “European 

Journal of Biophysics”, “Scientific Reports”, “Molecular Basis of Disease”, “American 

Heart Journal”, “International Journal of Molecular Sciences”, “Drug Design, 

Development and Therapy”. 

5


4) Chapter/book peer-reviewer for the pharmacological textbooks/pharmaceutical 

monographs: “Remington: The Science and Practice of Pharmacy” (22 nd edition, 2012) & 

“Remington Education: Pharmaceutics” (Author: Shelley Chambers Fox, scheduled for 

publication in 2013), both by publisher: “Pharmaceutical Press”, Philadelphia, PA, USA. 

Patents: 

1) Provisional patent entitled: “Adrenal GRK2 Activity as a Therapeutic Target for 

Heart Failure”, Patent ID: KOC_WAL.001, Inventors: Dr. Lymperopoulos, A., 

and Dr. Koch, W.J. Filed with the “Office of Technology Transfer”, Thomas 

Jefferson University, Philadelphia, PA, 19107, USA. Granted on 01/12/2007, 

present status: active. 

2) Provisional patent entitled: “Therapeutic strategies for lowering aldosterone levels 

post-myocardial infarction and in heart failure”. U.S. Provisional Patent 

Application #61/389,819. Inventors: Dr. Lymperopoulos, A., and Dr. Koch, W.J. 

Filed by the “Office of Technology Transfer”, Nova Southeastern University, Fort 

Lauderdale, FL 33314, USA, on 10/05/2010. 

Peer-reviewed Publications: 

1) Bathgate-Siryk, A., Dabul, S., Pandya, K., Walklett, K., Rengo, G., Cannavo, A., 

De Lucia, C., Liccardo, D., Gao, E., Leosco, D., Koch, W.J., Lymperopoulos, A. 

Negative Impact of β-Arrestin-1 on Post-Myocardial Infarction Heart Failure via 

Cardiac and Adrenal-Dependent Neurohormonal Mechanisms. Hypertension. 63: 

404-412 (2014). 

2) Lymperopoulos, A., Garcia, D., Walklett, K. Pharmacogenetics of cardiac 

inotropy. Pharmacogenomics 15: 1807-1821 (2014). Review. 

3) Drosatos, K., Lymperopoulos, A., Kennel, P.J., Pollak, N., Schulze, P.C., 

Goldberg, I.J. Pathophysiology of Sepsis-Related Cardiac Dysfunction: Driven by 

Inflammation, Energy Mismanagement, or Both Curr. Heart Fail. Rep. 2014 Dec 

5. [Epub ahead of print]. Invited Review. 

4) Lymperopoulos, A., French, F. Pharmacogenomics of heart failure. Methods Mol. 

Biol. 1175: 245-257 (2014). Invited Book Chapter. 

5) Lymperopoulos, A., Negussie, S. βArrestins in Cardiac G Protein-Coupled 

Receptor Signaling and Function: Partners in Crime or "Good Cop, Bad Cop" Int. 

J. Mol. Sci. 14: 24726-24741 (2013). Review. 

6


6) Salazar, N.C., Vallejos, X., Siryk, A., Rengo, G., Cannavo, A., Liccardo, D., De Lucia, C., Gao, 

E., Leosco, D., Koch, W.J., Lymperopoulos, A. GRK2 blockade with betaARKct is essential 

for cardiac beta2-adrenergic receptor signaling towards increased contractility. Cell 

Commun. Signal. 11: 64 (2013) 

7) Lymperopoulos, A., Rengo, G., Koch, W.J. Adrenergic Nervous System in Heart Failure: 

Pathophysiology and Therapy. Circ. Res. 113: 739-753 (2013). Invited Review. 

8) Siryk-Bathgate, A., Dabul, S., Lymperopoulos, A. Current and future G protein-coupled 

receptor signaling targets for heart failure therapy. Drug Des. Devel. Ther. 7: 1209-1222 

(2013). Invited Review. 

9) Lymperopoulos, A., Bathgate, A. Arrestins in the cardiovascular system. Prog. Mol. Biol. 

Transl. Sci. 118: 297-334 (2013). Invited Book Chapter. 

10) Lymperopoulos, A., Negussie, S., Walklett, K. Research Highlights: Adrenergic receptor 

pharmacogenetics in heart failure. Pharmacogenomics. 14: 1545-1549 (2013). Invited 

“Research Highlights” article. 

11) Lymperopoulos, A. Physiology and pharmacology of the cardiovascular adrenergic system. 

Front. Physiol. 4: 240 (2013). Invited Review. 

12) Lymperopoulos, A., Bathgate, A. Pharmacogenomics of the heptahelical receptor 

regulators G-protein-coupled receptor kinases and arrestins: the known and the unknown. 

Pharmacogenomics 13: 323-341 (2012). Review. 

13) Lymperopoulos, A. Ischemic Emergency: Endothelial Cells Have Their Own "Adrenaline 

Shot" at Hand. Hypertension 60: 12-14 (2012). Invited editorial commentary. 

14) Rengo, G., Lymperopoulos, A., Zincarelli, C., Femminella, G.D., Liccardo, D., Pagano, G., de 

Lucia, C., Cannavo, A., Gargiulo, P., Ferrara, N., Perrone Filardi, P., Koch, W.J., Leosco, D. 

Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2) -adrenoceptorcatecholamine 

production axis in heart failure. Br. J. Pharmacol. 166: 2430-2440 (2012) 

15) Rengo, G., Zincarelli, C., Femminella, G.D., Liccardo, D., Pagano, G., de Lucia, C., Altobelli, 

G.G., Cimini, V., Ruggiero, D., Perrone-Filardi, P., Gao, E., Ferrara, N., Lymperopoulos, A., 

Koch, W.J., Leosco, D. Myocardial β(2)-adrenergic receptor gene delivery promotes 

coordinated cardiac adaptive remodeling and angiogenesis in heart failure. Br. J. 

Pharmacol. 166: 2348-2361 (2012) 

7


16) Ansari, R.A., Rizvi, S.A., Husain, K., Lymperopoulos, A., Berndt, W.O. Effect of sulfhydryl 

modification on rat kidney basolateral plasma membrane transport function. Bull. Environ. 

Contam. Toxicol. 89: 699-703 (2012) 

17) Rengo, G., Perrone-Filardi, P., Femminella, G.D., Liccardo, D., Zincarelli, C., de Lucia, C., 

Pagano, G., Marsico, F., Lymperopoulos, A., Leosco, D. Targeting the β-Adrenergic 

Receptor System Through G-Protein-Coupled Receptor Kinase 2: A New Paradigm for 

Therapy and Prognostic Evaluation in Heart Failure: From Bench to Bedside. Circ. Heart 

Fail. 5: 385-391 (2012). Review. 

18) Lymperopoulos, A. Beta-arrestin Biased Agonism/Antagonism at Cardiovascular Seven 

Transmembrane- spanning Receptors. Curr. Pharm. Des. 18: 192-198 (2012). Invited 

review. 

19) Lymperopoulos, A., Rengo, G., Koch, W.J. GRK2 Inhibition in Heart Failure: Something Old, 

Something New. Curr. Pharm. Des. 18: 186-191 (2012). Invited review. 

20) Lymperopoulos, A., Rengo, G., Zincarelli, C., Kim, J., Koch, W.J. Adrenal β−arrestin 1 

inhibition in vivo attenuates post-myocardial infarction progression to heart failure and 

adverse remodeling via reduction of circulating aldosterone levels. J. Am. Coll. Cardiol. 57: 

356-365 (2011) 

21) Lymperopoulos, A. GRK2 and β-arrestins in cardiovascular disease: something old, 

something new. Am. J. Cardiovasc. Dis. 1: 126-137 (2011). Invited review. 

22) Harvey, A.N., Nguyen, K., Lymperopoulos, A. GRK2 and Beta-Arrestins in Cardiovascular 

Disease: Established and Emerging Possibilities for Therapeutic Targeting. Curr. Mol. 

Pharmacol. 6: 317-326 (2013). Review. 

23) Nguyen, K., Kassimatis, T., Lymperopoulos, A. Impaired desensitization of a human 

polymorphic alpha2B-adrenergic receptor variant enhances its sympatho-inhibitory 

activity in chromaffin cells. Cell Commun. Signal. 9: 5 (2011) 

24) Jasmin, J.F., Rengo, G., Lymperopoulos, A., Gupta, R., Eaton, G.J., Quann, K., Gonzales, 

D.M., Mercier, I., Koch, W.J., Lisanti, M.P. Caveolin-1 Deficiency Exacerbates Cardiac 

Dysfunction and Reduces Survival in Mice with Myocardial Infarction. Am. J. Physiol. Heart 

Circ. Physiol. 300: H1274-H1281 (2011) 

25) Drosatos, K., Bharadwaj. K.G., Lymperopoulos, A., Ikeda, S., Khan, R., Hu, Y., Agarwal, R., 

Yu, S., Jiang, H., Steinberg, S.F., Blaner, W.S., Koch, W.J., Goldberg, I.J. Cardiomyocyte 

lipids impair {beta}-adrenergic receptor function via PKC activation. Am. J. Physiol. 

Endocrinol. Metab. 300: E489-E499 (2011) 

26) Rengo, G., Lymperopoulos, A., Leosco, D., Koch, W.J. GRK2 as a novel gene therapy target 

in heart failure. J. Mol. Cell. Cardiol. 50: 785-792 (2011). Review. 

8


27) Lymperopoulos, A., Rengo, G., Gao, E., Ebert, S.N., Dorn, G.W. 2nd, Koch, W.J. Reduction 

of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure 

progression and improves cardiac function after myocardial infarction. J. Biol. Chem. 285: 

16378-16386 (2010) 

28) Rengo, G., Leosco, D., Zincarelli, C., Marchese, M., Corbi, G., Liccardo, D., Filippelli, A., 

Ferrara, N., Lisanti, M.P., Koch, W.J., Lymperopoulos, A. Adrenal GRK2 lowering is an 

underlying mechanism for the beneficial sympathetic effects of exercise training in heart 

failure. Am. J. Physiol. Heart Circ. Physiol. 298: H2032-H2038 (2010) 

29) Kassimatis, T.I., Nomikos, A., Giannopoulou, I., Lymperopoulos, A., Moutzouris, D.A., 

Varakis, I., Nakopoulou, L. Transcription factor Sp1 expression is upregulated in human 

glomerulonephritis: correlation with pSmad2/3 and p300 expression and renal injury. Ren. 

Fail. 32: 243-253 (2010) 

30) Lymperopoulos, A., Rengo, G., Zincarelli, C., Kim, J., Soltys, S., Koch W.J. An adrenal β- 

arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone 

production in vitro and in vivo. Proc. Natl. Acad. Sci. USA 106: 5825-5830 (2009) 

31) Rengo, G., Lymperopoulos, A., Koch W.J. Future G-protein coupled receptor targets for 

treatment of heart failure. Curr. Treat. Options Cardiovasc. Med. 11: 328-338 (2009). 

Review. 

32) Rengo, G., Lymperopoulos, A., Zincarelli, C., Donniacuo, M., Soltys, S., Rabinowitz, J.E., 

Koch W.J. Myocardial adeno-associated virus serotype 6-betaARKct gene therapy 

improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. 

Circulation 119: 89-98 (2009) 

33) Lymperopoulos, A., Rengo, G., Zincarelli, C., Soltys, S., Koch W.J. Modulation of Adrenal 

Catecholamine Secretion by In Vivo Gene Transfer and Manipulation of G Protein-Coupled 

Receptor Kinase-2 Activity. Mol. Ther. 16: 302-307 (2008) 

34) Lymperopoulos, A., Rengo, G., Koch, W.J. Adrenal adrenoceptors in heart failure: Finetuning 

cardiac stimulation. Tr. Mol. Med. 13: 503-511 (2007). Invited review, featured 

cover article. 

35) Lymperopoulos, A., Rengo, G., Funakoshi, H., Eckhart, A.D., Koch, W.J. Adrenal GRK2 

upregulation mediates sympathetic overdrive in heart failure. Nat. Med. 13: 315-323 

(2007). Important Note: This journal (“Nature Medicine”) is the top primary research 

journal in Medicine (Research and Experimental), with an “Impact Factor” of 27.553 (2008 

ISI Journal Citation Reports). 

36) Leosco, D., Rengo, G., Iaccarino, G., Filippelli, A., Lymperopoulos, A., Zincarelli, C., 

Fortunato, F., Golino, L., Marchese, M., Esposito, G., Rapacciuolo, A., Rinaldi, B., Ferrara, 

N., Koch, W.J., Rengo, F. Exercise training and beta-blocker treatment ameliorate agedependent 

impairment of beta-adrenergic receptor signaling and enhance cardiac 

9


responsiveness to adrenergic stimulation. Am. J. Physiol. Heart Circ. Physiol. 293: H1596- 

H1603 (2007) 

37) Flordellis, C., Papathanasopoulos, P., Lymperopoulos, A., Matsoukas, J., Paris, H. Emerging 

therapeutic approaches multi-targeting receptor tyrosine kinases and g protein-coupled 

receptors in cardiovascular disease. Cardiovasc. Hematol. Agents Med. Chem. 5: 133-145 

(2007). Review 

38) Karkoulias, G., Mastrogianni, O., Ilias, I., Lymperopoulos, A., Taraviras, S., Tsopanoglou, N., 

Sitaras, N., Flordellis, C.S. Alpha 2-adrenergic receptors decrease DNA replication and cell 

proliferation and induce neurite outgrowth in transfected rat pheochromocytoma cells. 

Ann. N. Y. Acad. Sci. 1088: 335-345 (2006) 

39) Lymperopoulos, A., Karkoulias, G., Koch, W.J., Flordellis, C.S. alpha(2)-Adrenergic receptor 

subtype-specific activation of NF-kappaB in PC12 cells. Neurosci. Lett. 402: 210-215 (2006) 

40) Manolis, A.S., Patsouras, N., Ilias, I., Constantakopoulos, J., Pyriohou, A., Lymperopoulos, 

A., Spathas, D.H., Flordellis C.S. Lack of association between alpha2B-adrenergic receptor 

polymorphism and risk of restenosis following coronary angioplasty and stent 

implantation--preliminary report. Clin. Chem. Lab. Med. 44: 807-812 (2006) 

41) Karkoulias, G., Mastrogianni, O., Lymperopoulos, A., Paris, H., Flordellis, C. alpha(2)- 

Adrenergic receptors activate MAPK and Akt through a pathway involving arachidonic acid 

metabolism by cytochrome P450-dependent epoxygenase, matrix metalloproteinase 

activation and subtype-specific transactivation of EGFR. Cell. Signal. 18: 729-739 (2006) 

42) Flordellis, C., Paris, H., Karabinis, A., Lymperopoulos, A. Pharmacogenomics of 

adrenoceptors. Pharmacogenomics 5: 803-817 (2004). Review 

43) Taraviras, S., Olli-Lahdesmaki, T., Lymperopoulos, A., Charitonidou, D., Mavroidis, E., 

Kallio, J., Scheinin, M., Flordellis, C. α 2 -adrenergic receptor subtypes regulate neuronal 

differentiation of transfected PC12 cells through MAPK activation. Eur. J. Cell Biol. 81: 363- 

374 (2002) 

44) Schaak, S., Cayla, C., Lymperopoulos, A., Flordellis, C., Cussac, D., Denis, C., and Paris, H. 

Transcriptional down-regulation of the human α 2C -adrenergic receptor by cAMP. Mol. 

Pharmacol. 58: 821-827 (2000) 

Textbooks-Book Chapters: 

1) Lymperopoulos, A., and French, F. Pharmacogenomics of Heart Failure. In Qing 

Yan (Editor): Pharmacogenomics in Drug Discovery and Development, 2 nd 

Edition, Methods in Molecular Biology-Springer Protocols, UK: Humana Press, 

2014, pp. 245-257 (2014) 

10


2) Lymperopoulos, A., and Bathgate, A. Arrestins in the Cardiovascular System. In 

Louis M. Luttrell, editors: The Molecular Biology of Arrestins, Vol. 118, PMBTS, 

UK: Academic Press, 2013, pp. 297-334 (2013) 

3) Lymperopoulos, A., Rengo, G., Gao, E., Ebert, S.N., Dorn, G.W., and Koch, 

W.J. Adrenal-specific G protein-coupled receptor kinase (GRK)-2 deficiency 

reduces circulating catecholamine levels and improves cardiac function after 

myocardial infarction. In L. Eiden (Editor): Catecholamine Research in the 21st 

Century: Abstracts and Graphical Abstracts, 10th International Catecholamine 

Symposium 2012, Oxford, UK: Elsevier, 2013, p. 224, Theme H: Catecholamines 

in the Periphery (2013) 

4) Lymperopoulos, A., and Koch, W.J. Autonomic Pharmacology. In 

Pharmacology and Therapeutics: Principles to Practice (1st edn) (Waldman, S.A. 

and Terzic, A., eds), Part 1: Principles, Section 3: Systems pharmacology, 

Chapter 9: Autonomic Pharmacology, pp. 115-139, Saunders/Elsevier, ISBN: 978- 

1-4160-3291-5, Language: English (2009) 

5) Lymperopoulos, A., Pairas, G., Scheinin, M., and Flordellis, C. Decreased GRKmediated 

Phosphorylation of a Polymorphic α 2B -adrenergic Receptor in PC12 

Cells. 3rd HELLENIC FORUM ON BIOACTIVE PEPTIDES, P.A. 

Cordopatis, E. Manessi-Zoupa and G. Pairas (Eds.), TYPORAMA, pp. 259-273 

(2003) 

6) Manolis, A.S., Lymperopoulos, A., Bouga, E.A., Scheinin, M., and Flordellis, 

C.S. Significance of G-protein –coupled receptor polymorphisms: The case of α 2 - 

adrenergic receptor. Drug Discovery and Design: Medical Aspects, J.Matscoukas 

and T. Mavromoustakos (Eds.), IOS Press, Vol. 55: 299-304 (2002) 

Published Abstracts: 

1) Lymperopoulos, A., Rengo, G., Koch, W.J. Regulation of aldosterone levels by adrenal 

βarrestin-1 as a new molecular target in heart failure. J. Heart Disease, Vol. 8, Nr. 1, July 

2011, p. 117, Oral Presentation Abstract #467, 16 th World Congress on Heart Disease, 

Vancouver, BC, Canada, 23-26 July 2011 

2) Lymperopoulos, A., Rengo, G., Magafa, V., Cordopatis, P., Koch, W.J. Biased 

Agonism/Antagonism of Sartans and Angiotensin II Analogs for Angiotensin II 

Type 1 Receptor-Induced, β-Arrestin-Dependent Aldosterone Production in Heart 

Failure. Circ. Suppl. II, Vol. 122, Oral Presentation Abstract #10263, 2010 AHA 

Scientific Sessions, Chicago, IL, USA, 13-17 November 2010 

3) Jasmin, J.F., Rengo, G., Lymperopoulos, A., Gupta, R., Eaton, G., Quann, K., 

Gonzales, D., Mercier, I., Koch, W.J., Lisanti, M.P. Caveolin-1 Deficiency 

Exacerbates Cardiac Dysfunction and Reduces Survival in Mice with Myocardial 

Infarction. Circ. Suppl. II, Vol. 122, Poster Presentation Abstract #14567, 2010 

AHA Scientific Sessions, Chicago, IL, USA, 13-17 November 2010 

11


4) Lymperopoulos, A., Rengo, G., Magafa, V., Cordopatis, P., Koch, W.J. Biased 

Agonism/Antagonism of β-Arrestin activation by the Angiotensin II Type 1 

Receptor: A Study of Sartans and Angiotensin II Analogs Using Aldosterone 

Turnover as a Readout. J. Card. Fail. Suppl. 1 August 2010, Vol. 16, No 8, S30- 

S31, Abstract #088, 14th HFSA Annual Scientific Meeting, San Diego, CA, USA, 

12-15 September 2010 

5) Lymperopoulos, A., Rengo, G., Koch, W.J. Biased agonism/antagonism of β- 

arrestin activation by the angiotensin II type 1 receptor: a study of sartans and 

angiotensin II analogs using aldosterone turnover as a readout. Eur. Heart J. 

(2010) 31 (Suppl. 1): 1-296, p. 75, Abstract #P593, ESC Congress 2010, 

Stockholm, Sweden, 28 August-1 September 2010 

6) Lymperopoulos, A., Rengo, G., Gao, E., Zincarelli, C., Koch, W.J. Genetic 

deletion of β-arrestin-1 improves function of the infarcted heart by reducing 

cardiac β-adrenergic receptor desensitization and cardiotoxic neurohormonal 

overstimulation. Cardiovasc. Res., Vol. 87, Suppl. 1, S92-S93, Oral Presentation 

Abstract #302, Frontiers in Cardiovascular Biology Congress of the ESC Council 

on Basic Cardiovascular Sciences, Berlin, Germany, 16-19 July 2010 

7) Lymperopoulos, A., Rengo, G., Gao, E., Zincarelli, C., Koch, W.J. Genetic 

deletion of β-arrestin-1 improves function of the infarcted heart by reducing 

cardiac β-adrenergic receptor desensitization and cardiotoxic neurohormonal 

overstimulation. Circ. Suppl. II, Vol. 120, S1177, Oral Presentation Abstract 

#5935, 2009 AHA Scientific Sessions, Orlando, FL, USA, 14-18 November 2009 

8) Rengo, G., Lymperopoulos, A., Zincarelli, C., Femminella, G., Liccardo, D., 

Corbi, G., Fillipelli, A., Ferrara, N., Koch, W.J., Leosco, D. Beta-adrenergic 

blockade reduces sympathetic overactivation in heart failure and restores adrenal 

GRK2-alpha 2 -adrenergic receptor-catecholamine production axis. Circ. Suppl. II, 

Vol. 120, S801, Oral Presentation Abstract #3394, 2009 AHA Scientific Sessions, 

Orlando, FL, USA, 14-18 November 2009 

9) Zincarelli, C., Rengo, G., Golino, L., Lymperopoulos, A., Altobelli, G., Cimini, 

V., Marchese, M., De Lucia, C., Koch, W.J., Leosco, D. Cardiac β 1 -adrenergic 

receptor blockade promotes angiogenesis in the post-ischemic failing heart via 

activation of VEGF- and Akt-dependent signaling pathways. Circ. Suppl. II, Vol. 

120, S1053-S1054, Poster Presentation Abstract #5118, 2009 AHA Scientific 

Sessions, Orlando, FL, USA, 14-18 November 2009 

10) Lymperopoulos, A., Rengo, G., Gao, E., Koch, W.J. Genetic Deletion of β- 

arrestin-1 improves function of the infarcted heart by reducing cardiac β- 

adrenergic receptor desensitization and cardiotoxic neurohormonal 

overstimulation. J. Card. Fail. Suppl. 1 2009, Vol. 15, No 6, S7, Abstract #016, 

13th HFSA Annual Scientific Meeting, August 2009 

12


11) Lymperopoulos, A., Rengo, G., Zincarelli, C., Kim, J., Soltys, S., Koch, W.J. A 

Crucial Role for Adrenal β−Αrrestin 1 in Angiotensin II-Dependent Aldosterone 

Production During Post-Myocardial Infarction Heart Failure Progression. Poster 

presentation #P106, Basic Cardiovascular Sciences Conference 2009-Molecular 

Mechanisms of Cardiovascular Disease, Lake Las Vegas, NV, USA (July 20-23, 

2009) 

12) Rengo, G., Lymperopoulos, A., Zincarelli, C., Marchese, M., Rengo, A., 

Avallone, A., Filippelli, A., Ferrara, N., Koch, W.J., Leosco, D. Restoration of 

adrenal GRK2-mediated catecholamine production is an underlying mechanism 

for reduction of sympathetic activation by exercise training in heart failure. Eur. 

Heart J. 2009; Vol. 30 (Abstract Supplement): 132, European Society of 

Cardiology Congress 2009, Barcelona, Spain (29 August-2 September 2009) 

13) Lymperopoulos, A., Rengo, G., Gao, E., Moraca, S.R., Ebert, S.N., Dorn, G.W. 

2nd, Koch, W.J. Adrenal-Targeted GRK2 Gene Deletion Ameliorates 

Sympathetic Overstimulation and Improves Function of the Failing Heart. Circ. 

Suppl. II, Vol. 118, No 18, S360-S361, Abstract #1629, October 28, 2008 

14) Lymperopoulos, A., Rengo, G., Gao, E., Moraca, S.R., Ebert, S.N., Dorn, G.W. 

2nd, Koch, W.J. Adrenal-Targeted GRK2 Gene Deletion Ameliorates 

Sympathetic Overstimulation and Improves Function of the Failing Heart. J. Card. 

Fail. Suppl. 2008, Vol. 14, No 6, S34, Abstract #102, 12th HFSA Annual 

Scientific Meeting, August 2008 

15) Rengo, G., Lymperopoulos, A., Zincarelli, C., Donniacuo, M., Soltys, S., 

Rabinowitz, J.E., Koch W.J. Long-term AAV6-βARKct Myocardial Gene 

Therapy Improves Cardiac Function Via Restoration Of β-Adrenergic Receptor 

Signaling and Neurohormonal Status of The Failing Heart. Circ. Suppl. II, Vol. 

118, No 18, S286, Abstract #339, October 28, 2008 

16) Lymperopoulos, A., Rengo, G., Chuprun, J.K., Koch, W.J. Adrenal beta-arrestin 

1 mediates angiotensin II-induced aldosterone production in vitro and in vivo. 

Circ. Suppl. II, Vol. 116, No 16, II-158, Abstract #815, October 16, 2007 

17) Lymperopoulos, A., Rengo, G., Chuprun, J.K., Koch, W.J. Adrenal beta-arrestin 

1 mediates physiological production of aldosterone in vivo, J. Card. Fail. Suppl. 

2007, Vol. 13, No 6, S102, Abstract #097, 11th HFSA Annual Scientific Meeting, 

August 2007 

18) Rengo, G., Lymperopoulos, A., Zincarelli, C., Soltys, S., Koch W.J. Modulation 

of Catecholamine Secretion by In Vivo Gene Transfer of G Protein-Coupled 

Receptor Kinase (GRK) Or A GRK2 Inhibitor Peptide In The Adrenal Gland, 

Circ. Suppl. II, Vol. 116, No 16, II-158, Abstract #818, October 16, 2007 

13


19) Lymperopoulos, A., Funakoshi, H., Shapiro, M., Cohn, H.I., Eckhart, A.D., 

Angelotti, T., Koch, W.J. Adrenal G-protein coupled Receptor Kinase (GRK) 2 

activity is a potential novel bio-marker of sympathetic outflow in chronic heart 

failure, Circ. Suppl. II, Vol. 114, No 18, II-36, Abstract #318, October 31, 2006 

20) Lymperopoulos, A., Pleger. S.T., Eckhart, A.D., Koch, W.J. Adrenal G-protein 

Coupled Receptor Kinase 2 Up-regulation Mediates Catecholaminergic 

Overstimulation of the Failing Heart. Circ. Suppl. II, Vol. 112, No 17, II-80, 

Abstract #468, October 25, 2005 

21) Lymperopoulos, A. The impact of GPCR polymorphisms on medicinal 

chemistry. Lecture L31, 5th INTERNATIONAL CONFERENCE IN 

“MEDICINAL CHEMISTRY: DRUG DISCOVERY AND DESIGN”, Patras, 

Greece (2004) 

22) Lymperopoulos, A., Pairas, G., Scheinin, M., and Flordellis, C. Impaired 

agonist-promoted desensitization of a polymorphic α 2B -adrenergic receptor in 

PC12 cells. European Journal of Drug Metabolism and Pharmacokinetics, Vol. 

28, Nr. 1: Page 17 (2003) 

23) Lymperopoulos, A., Pandeli, E., Karkoulias, G., Mastroyianni, O., Pyriohou, A., 

and Flordellis, C. Epinephrine Induces the Activation of the Transcription Factors 

AP-1 and NF-κB in PC12 Cells Transfected with α 2 -Adrenergic Receptors. 

Review of Clinical Pharmacology and Pharmacokinetics, Greek Edition 2003, 21: 

32-33 (2003) 

24) Lymperopoulos, A., Taraviras, S., Mastroyianni, O., Stavropoulou, E., 

Kasimatis, T., and Flordellis, C. Phosphatidylinositol-3 Kinase (PI-3K) Mediates 

Epinephrine-Induced Survival and Differentiation of PC12- α 2 Cells. Review of 

Clinical Pharmacology and Pharmacokinetics, International Edition, 16: 15 (2002) 

25) Lymperopoulos, A., Schaak, S., Charitonidou, D., Cayla, C., Denis, C., Paris, H., 

and Flordellis, C. cAMP down-regulates α2C-adrenergic receptor at the 

transcriptional level in HepG2 cells. NATO/FEBS Advanced Study Institute- 

International Summer School on «Molecular Mechanisms of Signal 

Transduction», Island of Spetsai, Greece. Review of Clinical Pharmacology and 

Pharmacokinetics, International Edition, 13: 61 (1999) 

Research Financial Support: 

1) AHA Scientist Development Grant (SDG) Award (National Center) entitled: 

“Role of adrenal beta-arrestin-1 in angiotensin II-induced aldosterone production 

in post-infarct heart failure” (Award ID: 09SDG2010138), PI: Dr. Anastasios 

Lymperopoulos, Duration: 07/01/2009-06/30/2014, Gross Annual Funding: 

77,000 $ 

14


2) AHA Great Rivers (Formerly: Pennsylvania-Delaware) affiliate Post-Doctoral 

Research Fellowship, “Role of Adrenal GRKs in Regulation of Sympathetic 

Nervous System Activity in Heart Failure”, July 2005-July 2008, Thomas 

Jefferson University, Philadelphia, PA. PI: Dr. Walter J. Koch 

3) Co-Investigator, “Adrenal GRKs and Adrenergic Signaling in Heart Failure”, 

NIH Research Grant: R01 HL085503-01A1, April 2007-July 2009. PI: Dr. Walter 

J. Koch 

4) Nova Southeastern University`s President's Faculty Research & Development 

Grant (PFRDG)-FY 2014 (NSU intramural grant) entitled: “Angiotensin receptor 

blockers & beta-arrestin-dependent aldosterone production” (Award ID: PFRDG 

335320), PI: Dr. Anastasios Lymperopoulos, Duration: 08/01/2013-07/31/2014, 

Total Funding: 9,661 $ 

5) Nova Southeastern University`s Health Professions Division (HPD) Research 

Grant (NSU-HPD intramural grant) entitled: “Role of beta-arrestin-1 in 

aldosterone production from adrenocortical cells” (Award ID: 335797-RX- 

Lymperopoulos-BetaArrestin1), PI: Dr. Anastasios Lymperopoulos, Duration: 

10/01/2011-09/30/2012, Total Funding: 5,000 $ 

6) Co-Investigator, “Study of Signal Transduction of cloned α 2 -adrenergic receptors 

in homologous and heterologous cell lines”. BIOMED II Program, European 

Union Research Council, 1998-2001. PI: Dr. Chris S. Flordellis 

15

Curriculum Vitae - College of Pharmacy - Nova Southeastern ...

Create successful ePaper yourself

Delete template?

Save as template?